Stock Market Reviews

SRDX (Surmodics, Inc.) News

Get the latest news, insights, and market updates on SRDX (Surmodics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform
  EDEN PRAIRIE, Minn., October 29, 2025--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from a sex-specific analysis of 160 real-world acute, subacute, and chronic thrombotic limb ischemia patients from its PROWL registry study were presented by Dr. Peter Monteleone at the 37th Annual TCT Symposium in San Francisco, CA.
  Oct 29, 2025 - $SRDX
• SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
  Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
  Aug 12, 2025 - $SRDX
• SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
  Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
  Aug 8, 2025 - $SRDX
• SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
  SurModics (SRDX) delivered earnings and revenue surprises of +128.57% and +4.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 8, 2025 - $SRDX
• SurModics: Fiscal Q3 Earnings Snapshot
  SRDX) on Friday reported a loss of $5.3 million in its fiscal third quarter. On a per-share basis, the Eden Prairie, Minnesota-based company said it had a loss of 37 cents. Earnings, adjusted for costs related to mergers and acquisitions and amortization costs, came to 6 cents per share.
  Aug 8, 2025 - $SRDX
• Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
  EDEN PRAIRIE, Minn., August 08, 2025--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025.
  Aug 8, 2025 - $SRDX
• ICU Medical (ICUI) Surpasses Q2 Earnings and Revenue Estimates
  ICU Medical (ICUI) delivered earnings and revenue surprises of +45.83% and +0.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 7, 2025 - $SRDX
• Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8
  EDEN PRAIRIE, Minn., August 06, 2025--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8.
  Aug 6, 2025 - $SRDX
• Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates
  Evolus (EOLS) delivered earnings and revenue surprises of -166.67% and -16.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 5, 2025 - $SRDX
• Surmodics still recovering after June cyberattack
  Surmodics said that to its knowledge, the threat actor had not released any of its data or used it for any fraudulent purposes.
  Jul 3, 2025 - $SRDX